{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:43:35Z","timestamp":1791852215068,"version":"4.3.4"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2024,11,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The emergence of metallo-\u03b2-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed \u03b2-lactam\/ \u03b2-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime\u2013avibactam, using ceftazidime\u2013avibactam as a source of the \u03b2-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam\u2013avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam\/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-\u03b2-lactamase (\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>NDM<\/jats:sub>\n                      ) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam\u2013avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam\u2013avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam\u2013avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.00649-24","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:01:23Z","timestamp":1727686883000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of gradient strip diffusion for susceptibility testing of aztreonam\u2013avibactam in metallo-\u03b2-lactamase-producing Enterobacterales"],"prefix":"10.1128","volume":"62","author":[{"given":"Jamie K.","family":"Lemon","sequence":"first","affiliation":[{"name":"Northwell Health Clinical Laboratories, New York, New York, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Jankowsi-Romano","sequence":"additional","affiliation":[{"name":"Northwell Health Clinical Laboratories, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Duong","sequence":"additional","affiliation":[{"name":"Northwell Health Clinical Laboratories, New York, New York, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Juretschko","sequence":"additional","affiliation":[{"name":"Northwell Health Clinical Laboratories, New York, New York, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6306-7517","authenticated-orcid":true,"given":"Vincent A.","family":"Streva","sequence":"additional","affiliation":[{"name":"Northwell Health Clinical Laboratories, New York, New York, USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Uniondale, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00774-09"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.03.020"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1906.121515"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/249856"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05215-22"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00895"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11071717"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.19.2300209"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00397-20"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw741"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030383"},{"key":"e_1_3_3_14_2","volume-title":"CLSI standard M100","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. Performance standards for antimicrobial susceptibility testing. In CLSI standard M100, 34th ed. Clinical and Laboratory Standards Institute.","edition":"34"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01647-22"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01944-19"},{"key":"e_1_3_3_17_2","volume-title":"CLSI guideline M52","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Verification of commercial microbial identification and antimicrobial susceptibility testing systems. In CLSI guideline M52, 1st ed. Clinical and Laboratory Standards Institute.","edition":"1"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac268"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad276"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00269-20"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02238-20"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep29934"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00859-16"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00649-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00649-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:02:08Z","timestamp":1731488528000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00649-24"}},"subtitle":[],"editor":[{"given":"Patricia J.","family":"Simner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,13]]}},"alternative-id":["10.1128\/jcm.00649-24"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00649-24","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"2024-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00649-24"}}